Development and Validation of a Genotypic Assay to Quantify CXCR4- and CCR5-Tropic Human Immunodeficiency Virus Type-1 (HIV-1) Populations and a Comparison to Trofile
Daisy Ko, Sherry McLaughlin, Wenjie Deng, James I Mullins, Joan Dragavon, Socorro Harb, Robert W Coombs, Lisa M Frenkel
Open access · goldAbstract readComparative StudyValidation Study
Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 2 institutions in 1 country.
Daisy KoCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Sherry McLaughlinCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Wenjie DengDepartment of Microbiology, University of Washington, Seattle, WA 98195, USA.
James I MullinsDepartment of Microbiology, University of Washington, Seattle, WA 98195, USA.
Joan DragavonDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
Socorro HarbDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.ORCID 0009-0005-3140-6016
Robert W CoombsDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA.
Lisa M FrenkelCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.ORCID 0000-0001-9566-8959
University of Washington · USInfectious Disease Research Institute · US
Funding
LOC-IMPAACT Leadership GroupPharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant Women in the USUM1AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI Sharon A Nachman · 2011 to 2026
$278.1M
Statistical and Data Management Center-Pediatric,Adolescent, and Maternal CTGUM1AI068616 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Sean Scott Brummel, Marlene Ann Cooper · 2011 to 2026
$155.6M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI EDWIN ROBERTO ORELLANA · 1988 to 2026
$104.9M
LC - IMPAACT Leadership GroupUM1AI106716 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
HIV-1 typically infects cells via the CD4 receptor and CCR5 or CXCR4 co-receptors. Maraviroc is a CCR5-specific viral entry inhibitor; knowledge of viral co-receptor specificity is important prior to usage. We developed and validated an economical V3-
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Development and Validation of a Genotypic Assay to Quantify CXCR4- and CCR5-Tropic Human Immunodeficiency Virus Type-1 (HIV-1) Populations and a Comparison to Trofile · full record | OpenQuestion